No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Saturday, October 25, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Business

Analysts see huge upside in Teva

by TheAdviserMagazine
3 months ago
in Business
Reading Time: 3 mins read
A A
Analysts see huge upside in Teva
Share on FacebookShare on TwitterShare on LInkedIn


Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) last week published its second quarter financial results in which it presented lower revenue but higher profit than predicted by the analysts – $4.2 billion and $0.66 per share respectively. Teva also raised sales guidance for branded drugs and annual profit guidance. On the day the report was published, Teva’s share price rose 1.8% on Wall Street but in the following days fell 8.6%. This morning Teva is down 4.74% on the Tel Aviv Stock Exchange (TASE).

Since the start of 2025, Teva has underperformed compared to other major companies in the sector. Since the start of the year the company’s share price has fallen 30.2% compared with an average fall of 4.8% in the S&P health care sector indices. The latest fall comes after a phenomenal year for Teva in 2024, in which it doubled its value. Today, after recent declines, the company’s stock has a market cap of $9 billion.

According to “The Wall Street Journal,” the average target price of 11 investment institutions covering Teva’s stock is $24.29, a 57.9% premium on the current share price, and almost all of them have positive recommendations for the stock.

Oppenheimer: “Excellent buying opportunity”

One of the investment banks whose price target for Teva’s stock is among the highest is Oppenheimer with a price target of $30, 95.1% higher than the price on the NYSE. Oppenheimer’s recommendation for Teva is “outperform.”

Oppenheimer writes, “In our opinion, the current market value of Teva’s stock does not reflect its future earnings potential, and constitutes an excellent buying opportunity for long-term investors.”

Oppenheimer adds, “Teva reported excellent results for the second quarter of the year and affirmed its strategic aims for 2027.” Teva’s aims for 2027 include a non-GAAP operating margin of 30%. In May Teva reported laying off 8% of its workforce – about 3,000 employees by 2027 – in order to save $700 million. The company’s CEO Richard Francis said after publication of the results last week that there is rapid progress in the plan, which is already generating annual savings for the company of $140 million in 2025.

Oppenheimer notes that achieving the 2027 aims needs significant growth in sales of branded drugs, operational efficiency and higher profit margins from branded drugs, which will allow creation of strong free cash flow. In their assessment, Teva will be able to achieve the aims earlier than expected. According to the Oppenheimer analysts, the drug Duvakitug, which is being developed together with Sanofi for gastrointestinal infections, is expected to begin phase 3 clinical trials in the fourth quarter, thus making Teva eligible for a payment of $500 million from Sanofi. In their assessment, the drug will be of equal importance to Copaxone in the future and may even overtake it in revenue in the far future.





RELATED ARTICLES




Teva again raises profit guidance


Israeli institutional investors bet on Teva


Teva launches startup challenge program


Teva gives aggressive guidance for innovative drugs






The sale of Teva’s active ingredients division will free up capital. Management said that a final decision will be made during the current quarter, and Oppenheimer estimates that its value will be $1.5-2 billion. “The US government places special emphasis on the sustainability of supply chains, and therefore this is likely to have a positive impact on the price that Teva is able to demand in the deal.”

Can rise by tens of percent?

Not only Oppenheimer believes in the Israeli pharmaceutical giant. A recent “Globes” survey of 14 institutional investors in the Israeli capital market found that many of them believed Teva’s stock is undervalued. For example, Migdal noted that it “currently trades at a 6.5-fold earnings multiple. Our assumption is that as confidence in revenue and profit levels in the coming years increases, the company will begin to trade at an earnings multiple that is more similar to ethical companies (branded drug manufacturers), which could result in a share price of $23-27.” This is while the stock is currently trading at a price that is over 50% lower.

Migdal believes that Teva is on the right track to get there, after over the past decade, “Succeeding in reducing debt 60%, significantly cutting expenses, improving production efficiency and creating a broader revenue mix, with a variety of new branded drugs. In addition, the company has built an impressive branded drug pipeline that is expected to provide it with a growth engine in the coming years.”

At the same time, Shmuel Ben-Arie, CIO at Pioneer Capital Management, also estimated last week in an interview with Globes that Teva is trading at a relatively low cash flow multiple, “and could easily rise 30%-40% in the coming year.”

Published by Globes, Israel business news – en.globes.co.il – on August 4, 2025.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2025.




Source link

Tags: analystsHugeTevaUpside
ShareTweetShare
Previous Post

10 Cheap, Beautiful Places To Retire

Next Post

Sorting Out Covid Vaccine Confusion: New and Conflicting Federal Policies Raise Questions

Related Posts

edit post
LendingClub, ABTC surge, Bitfarms, FHI slide: financials wrap

LendingClub, ABTC surge, Bitfarms, FHI slide: financials wrap

by TheAdviserMagazine
October 25, 2025
0

Oct. 25, 2025 10:10 AM ETIBN, FHI, SFBS, LC, ENVA, KNSL, BTC-USD, BITF, UPST, CRCL, ABTCBy: Max Gottlich, SA News...

edit post
Insiders Are Scooping Up Shares of a Miner, a Driller, and a Biotech

Insiders Are Scooping Up Shares of a Miner, a Driller, and a Biotech

by TheAdviserMagazine
October 25, 2025
0

Denys Yelmanov / iStock via Getty Images While insider buying is typically slower when markets are near all-time highs and...

edit post
I helped design rocket engines for NASA’s space shuttles. Here’s why businesses need AI as trustworthy as aerospace tech

I helped design rocket engines for NASA’s space shuttles. Here’s why businesses need AI as trustworthy as aerospace tech

by TheAdviserMagazine
October 25, 2025
0

When I was an aerospace engineer working on the NASA Space Shuttle Program, trust was mission-critical. Every bolt, every line...

edit post
Bharat Rasayan board okays stock split, issue of bonus shares

Bharat Rasayan board okays stock split, issue of bonus shares

by TheAdviserMagazine
October 25, 2025
0

Agro-chemical firm Bharat Rasayan's board has approved the sub-division of its equity shares and issue of bonus shares in a...

edit post
F&O Talk | Nifty takes breather after Diwali gains, 30,000 still a likely destination by next Diwali: Sudeep Shah

F&O Talk | Nifty takes breather after Diwali gains, 30,000 still a likely destination by next Diwali: Sudeep Shah

by TheAdviserMagazine
October 25, 2025
0

Markets continued their upward momentum for the fourth straight week, ending the Diwali-shortened trading period with modest gains. Optimism dominated...

edit post
Meet the billionaire couple who not only signed The Giving Pledge but actually delivered—donating nearly half their fortune while still alive

Meet the billionaire couple who not only signed The Giving Pledge but actually delivered—donating nearly half their fortune while still alive

by TheAdviserMagazine
October 25, 2025
0

The Giving Pledge was designed to hold the world’s richest people accountable for donating at least half their fortunes in...

Next Post
edit post
Sorting Out Covid Vaccine Confusion: New and Conflicting Federal Policies Raise Questions

Sorting Out Covid Vaccine Confusion: New and Conflicting Federal Policies Raise Questions

edit post
Prague-based Resistant AI secures strategic investment from Experian to combat APP fraud

Prague-based Resistant AI secures strategic investment from Experian to combat APP fraud

  • Trending
  • Comments
  • Latest
edit post
77-year-old popular furniture retailer closes store locations

77-year-old popular furniture retailer closes store locations

October 18, 2025
edit post
Pennsylvania House of Representatives Rejects Update to Child Custody Laws

Pennsylvania House of Representatives Rejects Update to Child Custody Laws

October 7, 2025
edit post
What to Do When a Loved One Dies in North Carolina

What to Do When a Loved One Dies in North Carolina

October 8, 2025
edit post
Probate vs. Non-Probate Assets: What’s the Difference?

Probate vs. Non-Probate Assets: What’s the Difference?

October 17, 2025
edit post
California Attorney Pleads Guilty For Role In 2M Ponzi Scheme

California Attorney Pleads Guilty For Role In $912M Ponzi Scheme

October 15, 2025
edit post
Baby Boomers Are Flocking to This Florida Town — but Not for the Weather

Baby Boomers Are Flocking to This Florida Town — but Not for the Weather

October 9, 2025
edit post
White House Crypto Czar Backs Michael Selig as ‘Excellent Choice’ To Lead CFTC

White House Crypto Czar Backs Michael Selig as ‘Excellent Choice’ To Lead CFTC

0
edit post
How Many Dimes Are In 5 Dollars?

How Many Dimes Are In 5 Dollars?

0
edit post
Mortgage Rates Inch Toward 6% as Fed Weighs October Cut

Mortgage Rates Inch Toward 6% as Fed Weighs October Cut

0
edit post
Andel Raises .5M to Solve the Brand-Name Drug Affordability Crisis Through Cooperative Buying Power – AlleyWatch

Andel Raises $4.5M to Solve the Brand-Name Drug Affordability Crisis Through Cooperative Buying Power – AlleyWatch

0
edit post
F&O Talk | Nifty takes breather after Diwali gains, 30,000 still a likely destination by next Diwali: Sudeep Shah

F&O Talk | Nifty takes breather after Diwali gains, 30,000 still a likely destination by next Diwali: Sudeep Shah

0
edit post
Silver Pullback Tests Bulls’ Nerves, but Structural Shortages Remain Intact

Silver Pullback Tests Bulls’ Nerves, but Structural Shortages Remain Intact

0
edit post
White House Crypto Czar Backs Michael Selig as ‘Excellent Choice’ To Lead CFTC

White House Crypto Czar Backs Michael Selig as ‘Excellent Choice’ To Lead CFTC

October 25, 2025
edit post
How Many Dimes Are In 5 Dollars?

How Many Dimes Are In 5 Dollars?

October 25, 2025
edit post
A Brief History of the Enduring American Embargo against Cuba

A Brief History of the Enduring American Embargo against Cuba

October 25, 2025
edit post
LendingClub, ABTC surge, Bitfarms, FHI slide: financials wrap

LendingClub, ABTC surge, Bitfarms, FHI slide: financials wrap

October 25, 2025
edit post
Hotstocks KW 43 / 2025 – Solaraktien für mehr Sonne im Depot!

Hotstocks KW 43 / 2025 – Solaraktien für mehr Sonne im Depot!

October 25, 2025
edit post
Insiders Are Scooping Up Shares of a Miner, a Driller, and a Biotech

Insiders Are Scooping Up Shares of a Miner, a Driller, and a Biotech

October 25, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • White House Crypto Czar Backs Michael Selig as ‘Excellent Choice’ To Lead CFTC
  • How Many Dimes Are In 5 Dollars?
  • A Brief History of the Enduring American Embargo against Cuba
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.